GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hainan Poly Pharm Co Ltd (SZSE:300630) » Definitions » Beta

Hainan Poly Pharm Co (SZSE:300630) Beta : 1.38 (As of Dec. 13, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Hainan Poly Pharm Co Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-13), Hainan Poly Pharm Co's Beta is 1.38.


Hainan Poly Pharm Co Beta Historical Data

The historical data trend for Hainan Poly Pharm Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hainan Poly Pharm Co Beta Chart

Hainan Poly Pharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.75 0.99 1.31 1.52

Hainan Poly Pharm Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 1.52 1.62 1.40 1.37

Competitive Comparison of Hainan Poly Pharm Co's Beta

For the Drug Manufacturers - Specialty & Generic subindustry, Hainan Poly Pharm Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hainan Poly Pharm Co's Beta Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hainan Poly Pharm Co's Beta distribution charts can be found below:

* The bar in red indicates where Hainan Poly Pharm Co's Beta falls into.



Hainan Poly Pharm Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Hainan Poly Pharm Co  (SZSE:300630) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Hainan Poly Pharm Co Beta Related Terms

Thank you for viewing the detailed overview of Hainan Poly Pharm Co's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Hainan Poly Pharm Co Business Description

Traded in Other Exchanges
N/A
Address
No.1509 Binsheng Road, 10th Floor, Zhejiang Province, Hangzhou, CHN, 310051
Hainan Poly Pharm Co Ltd is a pharmaceutical manufacturer in China. It manufactures injections, oral solid formulations, dry suspension, and other active pharmaceutical ingredients. The products offered by the company include Azithromycin for Injection, Ganciclovir Sodium for Injection. Octreotide Acetate Injection, Trimebutine Maleate tablets, Desloratadine, Trimebutine Maleate, and GANCICLOVIR among others.
Executives
Fan De Zhu Independent director
Xie Hui Fang Supervisors
Pu Jian Executives
Xu Zhao Securities Affairs Representative
Shen Shi Hua Executives
Zhou Mao Directors, Directors, and Executives

Hainan Poly Pharm Co Headlines

No Headlines